|
|
Article: FoldRx Kicks Off Phase II/III Against Genetic Neuropathy.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
FoldRx Pharmaceuticals Inc. started the Phase II/III study with Fx-1006A for the first niche disease targeted - familial amyloid polyneuropathy, a fatal genetic disorder that afflicts about 10,000 people worldwide.
Richard Labaudiniere, president and CEO of Cambridge, Mass.-based FoldRx, said the firm expects to have data from the trial by 2009, and to file for approval shortly thereafter.
"This will be one of the first examples of an oral drug to correct protein misfolding and stop disease progression," he said, noting that the company has a separate, yeast-based platform developed from work done by Susan Lindquist, professor ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|